Hybio Pharmaceutical Co Ltd SZSE:300199:
SAYS ITS LIRAGLUTIDE INJECTION APPROVED BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR TREATING ADULT TYPE 2 DIABETES
Reuters
Hybio Pharmaceutical's Liraglutide Injection Approved By China's National Medical Products Administration
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- SZSE:300199
- Language
- English
Hybio Pharmaceutical Co Ltd SZSE:300199: